Outlook on PI3K/AKT/mTOR inhibition in acute leukemia

L Fransecky, LH Mochmann, CD Baldus - Molecular and cellular therapies, 2015 - Springer
Technological advances allowing high throughput analyses across numerous cancer
tissues have allowed much progress in understanding complex cellular signaling. In the …

Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia

AM Martelli, C Evangelisti, F Chiarini… - Expert opinion on …, 2009 - Taylor & Francis
Background: The PI3K/Akt/mammalian target of rapamycin (mTOR) signaling pathway plays
a central role in cell growth, proliferation and survival not only under physiological …

Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia

BA Carneiro, JB Kaplan, JK Altman… - Cancer Biology & …, 2015 - Taylor & Francis
An accumulating understanding of the complex pathogenesis of acute myeloid leukemia
(AML) continues to lead to promising therapeutic approaches. Among the key aberrant …

Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis

J Bertacchini, M Guida, B Accordi, L Mediani… - Leukemia, 2014 - nature.com
Acute myeloid leukemia (AML) primary cells express high levels of phosphorylated Akt, a
master regulator of cellular functions regarded as a promising drug target. By means of …

Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia

KM Kampa-Schittenhelm, MC Heinrich, F Akmut… - Molecular cancer, 2013 - Springer
Background Dysregulation of the PI3Kinase/AKT pathway is involved in the pathogenesis of
many human malignancies. In acute leukemia, the AKT pathway is frequently activated …

Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia

S Badura, T Tesanovic, H Pfeifer, S Wystub… - PloS one, 2013 - journals.plos.org
Purpose Aberrant PI3K/AKT/mTOR signaling has been linked to oncogenesis and therapy
resistance in various malignancies including leukemias. In Philadelphia chromosome (Ph) …

[HTML][HTML] The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients

AM Martelli, C Evangelisti, F Chiarini, JA McCubrey - Oncotarget, 2010 - ncbi.nlm.nih.gov
Abstract The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin
(mTOR) signaling axis plays a central role in cell proliferation, growth, and survival under …

The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells

I Nepstad, KJ Hatfield, IS Grønningsæter… - International journal of …, 2020 - mdpi.com
Acute myeloid leukemia (AML) is a heterogeneous group of diseases characterized by
uncontrolled proliferation of hematopoietic stem cells in the bone marrow. Malignant cell …

Targeting the mTOR pathway in leukemia

S Dinner, LC Platanias - Journal of Cellular Biochemistry, 2016 - Wiley Online Library
Optimal function of multiple intracellular signaling pathways is essential for normal
regulation of cellular transcription, translation, growth, proliferation, and survival …

Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside

AM Martelli, PL Tazzari, C Evangelisti… - Current medicinal …, 2007 - ingentaconnect.com
The phosphatidylinositol 3-kinase (PI3K)/Akt (protein kinase B, PKB)/mammalian Target Of
Rapamycin (mTOR) signaling pathway plays a critical role in many cellular functions which …